Cargando…

Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers

INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Miku, Fujita, Retsu, Sato, Tomoaki, Sato, Ryohei, Kato, Yasuyuki, Nagasawa, Mitsuaki, Matsumoto, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339081/
https://www.ncbi.nlm.nih.gov/pubmed/35921965
http://dx.doi.org/10.1016/j.jiac.2022.07.006
_version_ 1784760100140875776
author Tamura, Miku
Fujita, Retsu
Sato, Tomoaki
Sato, Ryohei
Kato, Yasuyuki
Nagasawa, Mitsuaki
Matsumoto, Tetsuya
author_facet Tamura, Miku
Fujita, Retsu
Sato, Tomoaki
Sato, Ryohei
Kato, Yasuyuki
Nagasawa, Mitsuaki
Matsumoto, Tetsuya
author_sort Tamura, Miku
collection PubMed
description INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observational study on 187 healthcare workers and other personnel and healthy adults at least eight months after vaccination at the International University of Health and Welfare. RESULTS: The baseline (before the third dose of BNT162b2) anti-receptor binding domain (RBD) IgG level was 569[377–943] AU/mL 245[240–250] days after the second dose. The mean antibody titer of participants aged 20–29 years was 4.6 times higher than that of participants aged 70–79 years. After booster vaccination, serum anti-RBD antibody levels were elevated in all participants with a median titer of 23,250[14,612–33,401] AU/mL 21[19–23] days after the third dose. The median post-booster antibody titers in the 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79 years age groups were 30.6, 33.0, 33.8, 27.4, 50.1, and 90.3 times, respectively, higher than the pre-booster ones. Antibody levels were 15% lower in daily drinkers compared to nondrinkers, suggesting that daily alcohol consumption can prevent antibody levels from increasing after vaccination. Our results show decreased antibody titers after two doses of the vaccine, especially in the elderly; however, the third dose of the vaccine resulted in a significant increase in antibody titers in all age groups. CONCLUSIONS: We provided information on antibody responses following primary and booster doses of the BNT162b2 mRNA COVID-19 vaccine in Japan.
format Online
Article
Text
id pubmed-9339081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93390812022-08-01 Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers Tamura, Miku Fujita, Retsu Sato, Tomoaki Sato, Ryohei Kato, Yasuyuki Nagasawa, Mitsuaki Matsumoto, Tetsuya J Infect Chemother Original Article INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observational study on 187 healthcare workers and other personnel and healthy adults at least eight months after vaccination at the International University of Health and Welfare. RESULTS: The baseline (before the third dose of BNT162b2) anti-receptor binding domain (RBD) IgG level was 569[377–943] AU/mL 245[240–250] days after the second dose. The mean antibody titer of participants aged 20–29 years was 4.6 times higher than that of participants aged 70–79 years. After booster vaccination, serum anti-RBD antibody levels were elevated in all participants with a median titer of 23,250[14,612–33,401] AU/mL 21[19–23] days after the third dose. The median post-booster antibody titers in the 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79 years age groups were 30.6, 33.0, 33.8, 27.4, 50.1, and 90.3 times, respectively, higher than the pre-booster ones. Antibody levels were 15% lower in daily drinkers compared to nondrinkers, suggesting that daily alcohol consumption can prevent antibody levels from increasing after vaccination. Our results show decreased antibody titers after two doses of the vaccine, especially in the elderly; however, the third dose of the vaccine resulted in a significant increase in antibody titers in all age groups. CONCLUSIONS: We provided information on antibody responses following primary and booster doses of the BNT162b2 mRNA COVID-19 vaccine in Japan. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-11 2022-07-31 /pmc/articles/PMC9339081/ /pubmed/35921965 http://dx.doi.org/10.1016/j.jiac.2022.07.006 Text en © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Tamura, Miku
Fujita, Retsu
Sato, Tomoaki
Sato, Ryohei
Kato, Yasuyuki
Nagasawa, Mitsuaki
Matsumoto, Tetsuya
Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title_full Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title_fullStr Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title_full_unstemmed Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title_short Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
title_sort immunological responses following the third dose of the bnt162b2 sars-cov-2 vaccine among japanese healthcare workers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339081/
https://www.ncbi.nlm.nih.gov/pubmed/35921965
http://dx.doi.org/10.1016/j.jiac.2022.07.006
work_keys_str_mv AT tamuramiku immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT fujitaretsu immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT satotomoaki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT satoryohei immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT katoyasuyuki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT nagasawamitsuaki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers
AT matsumototetsuya immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers